First Patient Dosed in Phase 1b Trial Testing Cirmtuzumab Add-on in HER2-negative Breast Cancer Patients
News
A pilot Phase 1 trial evaluating Oncternal Therapeutic’s investigational therapy cirmtuzumab as an add-on to standard chemotherapy for patients with advanced, HER2-negative breast cancer who cannot receive surgery has started dosing ... Read more